Skip to main content

United States News All stories

Every story in this section, newest first — page 346 of 373.

Grafa
Retail

McDonald's rival Jollibee jumps after announcing spin-off plans

Jollibee Foods Corp. shares saw their largest single-day rally in 18 years on Tuesday after the Philippine fast-food giant announced a transformative plan to spin off its international business and list it on a U.S. stock exchange.

The move is designed to decouple the company’s high-growth global brands from its stable, cash-generative domestic operations, providing investors with "targeted exposure" to two distinct equity stories.

Read more: McDonald's rival Jollibee jumps after announcing spin-off plans
Grafa
Technology

AMD unveils Ryzen AI embedded P100 & X100 at CES 2026

Advanced Micro Devices (NASDAQ:AMD) introduced a sweeping new portfolio of x86 processors at CES 2026, targeting the burgeoning "physical AI" market.

The new Ryzen AI Embedded P100 and X100 series are designed to bring high-performance, low-latency intelligence to automotive cockpits, industrial robotics, and autonomous systems, moving complex decision-making from the cloud to the device itself.

Read more: AMD unveils Ryzen AI embedded P100 & X100 at CES 2026
Grafa
Health

Moderna takes on traditional flu vaccines with global filings for mRNA-1010

Moderna (NASDAQ:MRNA) officially moved to challenge the multi-billion-dollar seasonal influenza market today, submitting marketing authorization applications for its investigational vaccine, mRNA-1010, to regulators in the U.S., Europe, Canada, and Australia.

Read more: Moderna takes on traditional flu vaccines with global filings for mRNA-1010
Grafa
Health

Zenas BioPharma announces positive Phase 3 results for obexelimab in IgG4-related disease

Zenas BioPharma (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company focused on developing transformative immunology-based therapies for autoimmune diseases, today announced positive topline results from the Phase 3 INDIGO registrational trial evaluating obexelimab in patients with Immunoglobulin G4-Related Disease (IgG4-RD).

Read more: Zenas BioPharma announces positive Phase 3 results for obexelimab in IgG4-related disease
Grafa
Health

Neumora’s Alzheimer’s candidate slashes agitation scores in early trial

Neumora Therapeutics (NASDAQ:NMRA), a clinical-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric disorders and neurodegenerative diseases, today reported positive topline results from a Phase 1b signal-seeking study evaluating NMRA-511 as a potential treatment for agitation in patients with Alzheimer's disease.

Read more: Neumora’s Alzheimer’s candidate slashes agitation scores in early trial
Grafa
Health

Gyre Therapeutics clears regulatory path for first-in-class liver fibrosis drug in China

Gyre Therapeutics (NASDAQ:GYRE) is moving toward a landmark commercial entry in China after securing alignment with the Center for Drug Evaluation (CDE) on a conditional approval pathway for its lead anti-fibrotic candidate, Hydronidone (F351).

Read more: Gyre Therapeutics clears regulatory path for first-in-class liver fibrosis drug in China
Grafa

Lucid production doubles in 2025 as Gravity SUV gains traction

Lucid Group (NASDAQ:LCID) reported a massive surge in manufacturing activity for 2025, successfully doubling its annual production as it ramps up deliveries of its new Gravity SUV.

The California-based luxury EV maker announced Monday that it produced 18,378 vehicles for the full year, a 104% increase over 2024, narrowly beating analyst estimates of approximately 17,910 units.

Read more: Lucid production doubles in 2025 as Gravity SUV gains traction
Grafa
Defence

Parsons secures $392M federal biometrics contract for national security

Parsons Corporation (NYSE:PSN) announced on Monday that it has been awarded a ten-year, $392 million single-award contract by an undisclosed federal customer.

The win represents "new work" for the Chantilly-based defense technology provider, further solidifying its position in the rapidly expanding market for mobile identity management and biometric security.

Read more: Parsons secures $392M federal biometrics contract for national security